ABVC BioPharma, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-7.9M | $-4.9M | $-7.8M | $-16.4M | $-12.8M | $-10.6M | $-3.9M | $-6.1M |
| Depreciation & Amortization | — | — | — | $23.8K | $12.0K | — | — | — |
| Depreciation | $25.3K | $32.0K | $28.5K | $23.8K | $12.0K | $37.1K | $55.1K | $43.6K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $4.1M | $2.8M | $185.9K | $7.0M | $5.3M | $4.1M | $22.3K | $28.8K |
| Net Cash from Operating Activities | $-3.0M | $-1.8M | $-4.2M | $-7.4M | $-7.6M | $-4.6M | $-3.1M | $-900.5K |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | $21.2K | $119.7K | $17.5K | — | — | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-1.2M | — | $-360.2K | $-1.7M | $-806.0K | $-225.4K | $-35.3K | $-156.4K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $4.6M | $2.0M | $3.9M | $4.0M | $10.0M | $9.6M | $3.1M | $896.9K |
| Net Change in Cash | $463.2K | $147.0K | $-674.9K | $-5.2M | $1.6M | $4.8M | $-82.3K | $-164.1K |
| Free Cash Flow | — | — | $-4.2M | $-7.5M | $-7.6M | — | — | — |